Sleuth reads sell-side research from 35+ banks and research firms and puts each analyst’s forecasts, timelines, and views into the dataset for your question. Click any value to open the report it came from and read it in full.
Analysts put their forecasts, timelines, and theses in long notes. Sleuth pulls out the numbers and views you need and lines them up next to the clinical and deal data for the same program.
Sleuth gathers recent notes on a drug or company and rolls the estimates into one consensus, with each analyst’s number and the full range beside it.
Sleuth puts the dates analysts expect for readouts, filings, and launches next to what the company itself has said.
Sleuth lines up each analyst’s price target, valuation, and thesis next to the trials and deals for the same asset, so you can weigh the bull case against the bear case.
Research from global and US healthcare banks, European brokers, independent analysts, and consulting firms, with archives back to 2017.
35+
Banks, brokers, and independent research firms.
500K+
Searchable in Sleuth, and open to read in full.
48 hours
Sleuth adds notes from many providers sooner.
Large-cap pharma and biotech coverage
Small- and mid-cap biotech coverage
European pharma and biotech coverage
Research on small-cap and non-US-listed biotechs
Industry reports and sector analysis
Translated into English and searchable with the rest of our China coverage.
Initiations and company deep dives
Earnings previews and recaps
Therapeutic area primers
Conference takeaways
KOL calls and physician surveys
Drug-level sales forecasts and consensus
Price targets and valuation models
M&A and licensing commentary
You don’t need a research subscription or an account with each bank. Every plan includes every report, free to search and read.
Open any report in Sleuth and read the whole thing, as often as you like.
Search every report by drug, company, or topic, and jump straight to the pages that match.
Download the datasets, charts, and decks built from the reports. The reports stay in Sleuth.
Run a project in Studio, or in Claude, ChatGPT, Copilot, or other AI tools, and Sleuth uses the same research.
Ask what analysts expect after Keytruda loses US patent protection in 2028, and Sleuth reads the 26 notes that cover it. Each analyst’s stance, view of subcutaneous Keytruda, and main risk goes in its own column, so you can see where they agree and where they diverge.
11 of the 19 notes that name a main risk point to the 2028 patent loss or how fast biosimilars take share.
One bank expects subcutaneous Keytruda to keep about 65% of sales by 2030. Another says it won’t do much against biosimilars.
Four of the five notes that pick a top replacement point to the Verona deal and its COPD drug, Ohtuvayre.
Pick a drug class, an asset, or a company you follow, fill in the brackets, and Sleuth builds the table.
“What are analysts saying about [drug class]? Show each one’s stance, thesis, peak sales view, and the catalysts they’re watching.”
“Pull every analyst’s peak sales estimate for [asset], with the consensus, the range, and the date of each note.”
“When do analysts expect [company]’s next readouts and filings, and what do they say would change their view?”